ESMO 2018 Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 37 articles

ESMO 2018: Preliminary results from TRITON2: A Phase II Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Repair Gene Alterations

ESMO 2018: The Best of Munich 2018 Congress Genitourinary Tumors, Prostate

ESMO 2018: Invited Discussant - Genomics of Prostate Cancer for Precision Medicine Based on DNA Repair Defects

ESMO 2018: Invited Discussant - Detection of Circulating Tumor DNA in mHSPC and LATITUDE Study

ESMO 2018: Invited Discussant - mCRPC with High Tumor Mutational Burden and a Phase I Dose-Escalation Study of 177Lu-PSMA-617 for mCRPC

ESMO 2018: Improving Treatment Outcome by Manipulating the Immune System

ESMO 2018: Randomized Trial of ADT + Enzalutamide Versus ADT + Bicalutamide in Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Cabazitaxel Treatment in mCRPC Clinical Trials Compared to Usual Care In CAPRI: An Observational Study In The Netherlands

ESMO 2018: Improving Outcome by Optimizing Combination and Sequencing of Treatments

ESMO 2018: Improving Treatment Outcome by Dissecting Heterogeneity

ESMO 2018: Results of PROSPER by Age and Region - A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide in Men with nmCRPC

ESMO 2018: Clinical Experience of 100 Consecutive Patients Treated with Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC

ESMO 2018: What is New in Metastatic Castration Resistant Prostate Cancer?

ESMO 2018: The Prognostic Value of the Proportion and Subtype Patterns of Intraductal Carcinoma with De Novo Metastatic Prostate Cancer: A Propensity Score Matching Study

ESMO 2018: STAMPEDE - Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Statin Use and Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated in the TROPIC Trial

ESMO 2018: Survival Results from STAMPEDE, Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden

ESMO 2018: Oligometastatic Disease - The Critical Need of a Multidisciplinary Approach for the Treatment of Prostate Cancer

ESMO 2018: Effects of Abiraterone Acetate plus Prednisone/Prednisolone in High and Low Risk Metastatic Hormone Sensitive Prostate Cancer

ESMO 2018: Update on Diagnosis and Treatment of Localized Prostate Cancer

1
2